Wednesday, September 27, 2023 8:03:08 AM
I've not accused you of being short doc, I simply said that the quote was from before you turned bearish and sold your shares. Some other people on this board however clearly do have ulterior motives.
Here's the thing about "that comment" doc. Yes it was from November 2022 before the Derms in the group had used the product, but it is evidence of that group being a breeding ground for "dis-information" i.e. FUD being spread by Abbvie shills. You're not so naive you believe that stopped when the product launched right doc? In 2022 the FUD was that Daxxify was only good because Revance doubled the dose. In 2023 the FUD is that Daxxify isn't even that good and only lasts a few weeks longer than Botox.
Doctors are also known to have a propensity for groupthink (and stubbornness) and specifically it seems this group of injectable providers were inexperienced in proper technique to generate excellent results with Daxxify.
You've admitted in past posts that Dermatologists don't really make money from injectables. Thus they clearly don't use a particularly high volume of Daxxify nor have the same incentives to find best techniques as businesses that do make money from them. Many injectable-focused aesthetics providers have seen the clear benefits of using Daxxify for both patients and themselves (particularly now with new pricing).
Do you have a better explanation for why so many aesthetics providers, some who post on this board, have discovered the appropriate technique for excellent Daxxify results—while these MDs in the FB group whose opinions you value so highly have not?
Good for you that you sold your shares before the most recent price collapse. I've been trading around this name for years. What happened in the past is now irrelevant.
Please screenshot and share any high-quality commentary from the FB group that proves me wrong if any exists.
Recent RVNC News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2024 01:29:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 11:32:37 AM
- Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm • PR Newswire (US) • 09/27/2024 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 11:15:36 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/16/2024 09:01:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:06:45 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 09/05/2024 09:27:28 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 09/05/2024 08:45:25 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 08/13/2024 01:29:06 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 08/12/2024 09:18:26 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc. • PR Newswire (US) • 08/12/2024 07:18:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:20:58 PM
- Crown Laboratories and Revance Announce Entry Into Merger Agreement • PR Newswire (US) • 08/12/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:00:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:34:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:07:57 PM
- Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 08/08/2024 08:05:00 PM
- Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • Business Wire • 08/01/2024 08:05:00 PM
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/14/2024 08:05:00 PM
- Revance to Participate in Upcoming Investor Conferences • Business Wire • 05/28/2024 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:33:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:08:10 PM
- Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 05/09/2024 08:06:00 PM
- Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia • Business Wire • 05/09/2024 08:05:00 PM
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 • Business Wire • 05/02/2024 08:05:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM